SUBSCRIBE: / eNewsletter
Many of the new treatment options for melanoma are very exciting as evidence of cancer advancement through science and clinical trials. However, we are still gathering post-market data on its associated side effects.
I met a young man several years ago in his thirties who was dying from metastatic melanoma. His parents were at his bedside every day at the inpatient oncology unit.
The anti-programmed-death-receptor-1 (PD-1) antibody, pembrolizumab (MK-3475), is effective and tolerable in patients with metastatic melanoma who have previously received another metastatic melanoma therapy.
What is the most common question that you are asked by patients with a new diagnosis of cancer?
The immunotherapy drug ipilimumab (Yervoy) is a monoclonal antibody against CTLA-4 that is approved for treatment of metastatic melanoma patients.
Recently, we completed a review of psychological and quality of life data literature on patients receiving targeted therapies. Very little is currently available on this topic. The few studies that were available dealt with imatinib (or
CHICAGO— Interim results of the ongoing phase III COMBI-d study reported at the 2014 annual meeting of the American Society of Clinical Oncology (ASCO) show that patients with BRAF V600E/K mutant metastatic melanoma had a signifi
Long-term results from a phase I study demonstrate that concurrent treatment with ipilimumab and nivolumab led to an unprecedented improvement in survival for patients with advanced melanoma.
The story of how the targeted therapies, immunotherapies, and combinations of these therapies have been developed for use in patients with advanced melanoma holds a number of important lessons for the development of agents for use in other tumor types.
On Monday during ASCO, Dr. Axel Hauschild reviewed the role of intralesional therapy in melanoma in a sub-session of the melanoma abstract review talk entitled “Evolving Utility of Intralesional Therapy for Melanoma.”
We've noticed that you're using an ad blocker
Our content is brought to you free of charge because of the support of our advertisers. To continue enjoying our content, please turn off your ad blocker.
